Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

D Cromer; JA Juno; D Khoury; A Reynaldi; AK Wheatley; SJ Kent; MP Davenport

Journal article

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

D Cromer, JA Juno, D Khoury, A Reynaldi, AK Wheatley, SJ Kent, MP Davenport

Nature Reviews Immunology | NATURE PORTFOLIO | Published : 2021

DOI: 10.1038/s41577-021-00550-x

Abstract

Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is central to long-term control of the current pandemic. Despite our rapidly advancing knowledge of immune memory to SARS-CoV-2, understanding how these responses translate into protection against reinfection at both the individual and population levels remains a major challenge. An ideal outcome following infection or after vaccination would be a highly protective and durable immunity that allows for the establishment of high levels of population immunity. However, current studies suggest a decay of neutralizing antibody responses in convalescent patients, and documented cases of SARS-CoV-2 reinfection are in..

View full abstract

University of Melbourne Researchers

Jennifer Juno Author

Adam Wheatley Author

Stephen Kent Author

Related Projects (3)

EUROPEAN AIDS VACCINE INITIATIVE 2020

A vaccine to prevent AIDS is urgently needed. The European Union recently awarded over 20 million euros to a European consortium, called EAV..

RATIONAL DESIGN OF NOVEL VACCINES FOR THE CONTROL OF INFLUENZA B

Current influenza vaccines elicit poor protection against viruses undergoing rapid change. We will define the conserved sites of vulnerabili..

ADDRESSING THE MAJOR CHALLENGES IN HIV VACCINE AND CURE RESEARCH

HIV remains one of the defining global health challenge of our times. 37 million people are living with HIV with 2 million new infections ea..

Grants

Awarded by Australian Research Council

Funding Acknowledgements

This study was supported by an Australian government Medical Research Future Fund award GNT2002073 (S.J.K., M.P.D. and A.K.W.), MRF2005544 (S.J.K., A.K.W., J.A.J. and M.P.D.), MRF2005760 (M.P.D.), the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (S.J.K.), an NHMRC program grant APP1149990 (S.J.K. and M.P.D.), NHMRC project grant GNT1162760 (A.K.W.), an NHMRC-EU collaborative award APP1115828 (S.J.K. and M.P.D.), and the European Union Horizon 2020 Research and Innovation Programme under grant agreement 681137 (S.J.K.). D.C., J.A.J., D.K., A.K.W., S.J.K. and M.P.D. are funded by NHMRC Fellowship/Investigator grants.